Related Experiment Videos
[125I] radioiodinated metaraminol: a new platelet-specific labeling agent
Abstract:
In our search for a platelet-specific labeling agent, metaraminol (MA), a low-toxic pharmaceutical for the treatment of hypotension and cardiogenic shock, attracted our attention. Its active incorporation and accumulation by platelets have been recognized. At first, the preparation of 125I radioiodinated metaraminol (125I-MA) was carried out using the chloramine-T method. Then, upon the harvest of platelets as platelet-rich plasma (PRP), their labeling with this new radiopharmaceutical was easily performed by incubation for 10 min at 37 degrees C. The cell-labeling efficiency was dependent on cell density, reaching 63.0% +/- 3.1% at 2.4 X 10(9) cells/ml. The specific incorporation of 125I-MA by an active transport system similar to that of 5-hydroxytryptamine (5-HT) as well as by passive diffusion was demonstrated. In in vitro studies, the unaltered state of 125I-MA-labeled platelets with their cellular functions fully retained was estimated. In vivo studies carried out in rabbits with induced thrombi in the femoral artery showed a rather rapid disappearance of the radioactivity from circulating blood, reaching a high thrombus-to-blood activity ratio of 19.8 +/- 4.3 within 30 min of the administration of 125I-MA-labeled autologous platelets. Thus, with the potential availability of 123I, 123I-MA-labeled platelets appear to be a promising agent for thrombus imaging using single-emission computed tomography (CT) studies.
Insights
Researchers developed a new radiopharmaceutical, 125I-metaraminol (125I-MA), for labeling platelets. This agent shows promise for imaging thrombi in vivo, potentially aiding in diagnosing vascular conditions.
Area of Science:
- Nuclear Medicine
- Hematology
- Radiopharmaceutical Chemistry
Background:
- Platelet-specific labeling agents are crucial for diagnostic imaging.
- Metaraminol (MA) is a low-toxicity pharmaceutical with known platelet incorporation.
- Developing novel radiotracers for platelet labeling is an active area of research.
Purpose of the Study:
- To prepare and characterize radioiodinated metaraminol (125I-MA) for platelet labeling.
- To evaluate the efficiency and mechanism of platelet labeling with 125I-MA.
- To assess the in vitro and in vivo performance of 125I-MA-labeled platelets for thrombus imaging.
Main Methods:
- Preparation of 125I-MA using the chloramine-T method.
- Labeling of human platelets with 125I-MA via incubation.
- Assessment of cell-labeling efficiency based on cell density.
- Demonstration of specific incorporation mechanisms (active transport and passive diffusion).
- In vitro evaluation of platelet function post-labeling.
- In vivo studies in rabbits with induced femoral artery thrombi to assess thrombus-to-blood activity ratios.
Main Results:
- Efficient platelet labeling with 125I-MA achieved (63.0% +/- 3.1% at 2.4 X 10(9) cells/ml).
- Platelet labeling demonstrated specific incorporation via active transport and passive diffusion.
- 125I-MA-labeled platelets retained unaltered cellular functions in vitro.
- In vivo studies showed rapid blood clearance and a high thrombus-to-blood activity ratio (19.8 +/- 4.3) within 30 minutes.
Conclusions:
- 125I-MA is an effective radiopharmaceutical for labeling platelets.
- 125I-MA-labeled platelets maintain their function and exhibit good thrombus targeting in vivo.
- 123I-MA-labeled platelets represent a promising candidate for single-emission computed tomography (SPECT) imaging of thrombi.